Animal Stem Cell Therapy Market Application, Specification Analysis, Size and Growth 2019 To 2024 – VaporBlash

Animal Stem Cell Therapy industry has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Animal Stem Cell Therapy market size to maintain the average annual growth rate of 0.111049325056 from 6.32 million $ in 2014 to 10.7 million $ in 2019, our analysts believe that in the next few years, Animal Stem Cell Therapy market size will be further expanded, we expect that by 2024, The market size of the Animal Stem Cell Therapy will reach 31.3 million $.

Alexa Reports has conveyed a report entitled Global Animal Stem Cell Therapy Market Research Report 2019 that is an unequivocal view of a couple of points of view, including development rate, mechanical advances and methodologies frameworks realized by the key players. The Animal Stem Cell Therapy Market report relies upon an aggregate examination of information, which is overcome fundamental and discretionary research. It gives a precise method to manage the present and prospective circumstance of this market.

Get a Sample Copy of this Report @ https://www.alexareports.com/report-sample/185764

The Animal Stem Cell Therapy market report looks at the financial status and anticipation of worldwide and key areas, in the possibility all things considered, types and application; this report analyzes the most striking players in major and worldwide regions, likewise partitions the Animal Stem Cell Therapy market by segments and applications/end organizations.

Major players profiled in the report are VETSTEM BIOPHARMA, MediVet Biologic, J-ARM, Celavet, Magellan Stem Cells, U.S. Stem Cell, Cells Power Japan, ANIMAL CELL THERAPIES, Animal Care Stem, Cell Therapy Sciences, VetCell Therapeutics, Animacel, Aratana Therapeutics

Product Type SegmentationDogsHorses

Industry SegmentationVeterinary HospitalsResearch Organizations

Additionally, Global Animal Stem Cell Therapy Market following points is included along with an in-depth study of each point:-

The Animal Stem Cell Therapy analysis incorporates historical data from 2014 to 2019 and predictions until 2024 helping to make the reports a valuable resource for industry executives, promotion, product and sales managers, advisers, analysts, and different people trying to find vital Animal Stem Cell Therapy industry data in readily accessible records with clearly exhibited tables and charts.

Avail discount while purchasing this report: https://www.alexareports.com/check-discount/185764

About Us:Alexa Reports is a globally celebrated premium market research service provider, with a strong legacy of empowering business with years of experience. We help our clients by implementing decision support system through progressive statistical surveying, in-depth market analysis, and reliable forecast data. Alexa Reports is a globally celebrated premium market research service provider, with a strong legacy of empowering business with years of experience. We help our clients by implementing decision support system through progressive statistical surveying, in-depth market analysis, and reliable forecast data.

Contact Us:Alexa ReportsPh no: +1-408-844-4624 / +91- 7030626939Email: [emailprotected]Site: https://www.alexareports.com

Read more here:
Animal Stem Cell Therapy Market Application, Specification Analysis, Size and Growth 2019 To 2024 - VaporBlash

ALS Stem Cell Therapy Developer Seeks Amendment to its AstroRx Trial – ALS News Today

Kadimastem plans to submit an amendment to the protocol of its ongoing Phase 1/2a trial in Israel assessing the use of AstroRx, an off-the-shelf stem cell therapy, for the treatment of amyotrophic lateral sclerosis (ALS).

The company wants to change the planned dosage in one of the studys cohorts and test repeated injections of a low dose of AstroRx, instead of the medium dose that was originally planned.

The request is based on positive interim data from the first set of five patients given a single intrathecal (into the spinal canal) injection of the lowest dose (100 x 106 cells) of AstroRx. At this dose, the therapy was found to be safe with no serious side effects or dose-limiting toxicities identified, according to the data, which was released in September.

Moreover, AstroRx significantly reduced disease progression after three months of treatment, compared to the start (baseline) of the trial. The ALS Functional Rating Scale revised (ALSFRS-R) score decreased on average by 0.87 per month during the three months before treatment; however, it started to increase again (on average by 0.26 per month) in the three months after treatment. The ALSFRS-R score is a validated assessment of disability progression, with lower scores indicating greater motor impairment.

Evidence suggests that poorly working astrocytes (cells which support and protect neurons) are involved in the progression of ALS. AstroRx is composed of healthy functional astrocytes, which have been derived from human embryonic stem cells. The treatment, injected into a patients spinal fluid, is thought to compensate for the diseased astrocytes and prevent the death of motor neurons, thereby slowing disease progression.

AstroRx was granted orphan drug status by the U.S. Food and Drug Administration in November 2018 for the treatment of ALS.

Preclinical (in the lab) studies have shown that AstroRx was safe, delayed disease onset, maintained muscle function, and increased survival in rodent models of ALS.

The ongoing open-label Phase 1/2a clinical trial (NCT03482050) is testing the safety and effectiveness of AstroRx in ALS patients. The trial is being conducted at Hadassah Ein-Kerem Medical Center in Israel where it recruited 21 patients withearly stagedisease.

The trials original protocol included four doses of AstroRx delivered into the spinal canal: a low (100 x 106 cells), medium (250 x 106 cells), or high (500 x 106 cells) dose.

The primary outcome of the trial is to assess the safety and tolerability of AstroRx. Secondary outcome measures include changes in patients ALSFRS-R scores, respiratory muscle strength, hand grip strength, limb muscle strength, and quality of life.

In cohort A, participants received a single low dose of the therapy. In cohort B, participants received a single medium dose of the therapy. Results from cohort A are expected to be reported by the end of 2019, and cohort B results are expected in 2020.

Based on the positive interim results from cohort A, Kadimastem is seeking to amend the therapy regime being assessed in cohort C and D, so that cohort C will receive two injections of the low dose (instead of the originally planned medium dose), with the injections being separated by two to three months. Results from this section of the trial are expected to be reported in the first half of 2021. Under the amendment, cohort D participants will receive the regimen originally planned for cohort C (repeated administration of the medium dose, 250 x 106). Cohort D dosing will be dependent on the results of the previous cohorts.

We are the first to treat ALS patients with astrocyte cells. Following our positive interim results, we look forward to achieving a prolonged therapeutic effect in the repeated low dose administration, bringing new hope for patients with this incurable disease Rami Epstein, CEO of Kadimastem, said in a press release.

Kadimastem expects to submit an investigational new drug application to the U.S. Food and Drug Administration by mid-2021 with the aim of testing AstroRx in a multi-center clinical trial, which will compare the current and frozen version of the therapy.

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.

Total Posts: 279

Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Tcnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.

Continued here:
ALS Stem Cell Therapy Developer Seeks Amendment to its AstroRx Trial - ALS News Today

Fred Hutch at ASH: Latest CAR T data BCMA, CD19, CD20 plus new insights on transplantation, gene therapy and more – Newswise

MEDIA CONTACT

Available for logged-in reporters only

For Immediate Release

Newswise SEATTLE Nov. 21, 2019 Fred Hutchinson Cancer Research Centers latest findings on CAR (chimeric antigen receptor) T-cell therapy, gene therapy, precision oncology, immune repair and transplantation will be featured at the 61st American Society of Hematology Annual Meeting and Exposition, which will be held Dec. 710 in Orlando, Florida.

Fred Hutch transplantation physician-scientist Dr. Stephanie Lee will become the new president of ASH at the end of the meeting, T-cell therapy pioneer Dr. Philip Greenberg will give the E. Donnall Thomas Lecture, and Dr. Andrew Cowan will present the latest on a new BCMA, or B-cell maturation antigen, CAR T-cell therapy for multiple myeloma. More details and other meeting highlights can be found below. All presentations will be held in the Orange County Convention Center.

Reporters requesting additional information or interviews, contact Molly McElroy who will be at the conference: mwmcelro@fredhutch.org, 206.941.8146 (cell).

IMMUNOTHERAPY

See preliminary results of a Phase 1 multiple myeloma trial with a CAR T-cell therapy combined with a repurposed Alzheimers drug, discussion of a new CD20 CAR T trial, plus various deep dives on the science of how CD19 CAR T-cell therapy works and how to improve it.

BCMA CAR T-CELL THERAPY / MULTIPLE MYELOMA

Efficacy and safety of fully human BCMA CAR T cells in combination with a gamma secretase inhibitor to increase BCMA surface expression in patients with relapsed or refractory multiple myelomaFred Hutch scientists are developing a novel immunotherapy approach for multiple myeloma, which involves a CAR T cell that targets BCMA proteins on multiple myeloma cells, plus a drug called a gamma secretase inhibitor, which increases the BCMA target on cancer cells. In an oral presentation, Dr. Andrew Cowan will present promising results from the first cohort of patients on the trial, all of whom responded to the treatment. The researchers published earlier findings of the trial in Blood in September.Abstract No. 204 (oral presentation)Saturday, Dec. 7, 1:15 p.m.Valencia A (W415A), Level 4

Response to BCMA CART cells correlates with pretreatment target density and is improved by small-molecule inhibition of gamma secretase Dr. Damian Green will present findings from multiple myeloma patients that demonstrate a relationship between the number of BCMA targets on multiple myeloma cells and response to a BCMA-directed CAR T-cell therapy. The findings suggest that using a gamma secretase inhibitor to increase the amount of BCMAs on the cell surface could make CAR T work better. Abstract No. 1856 (poster presentation)Saturday, Dec. 7, 5:307:30 p.m.Hall B, Level 2

CD19 CAR T-CELL THERAPIES

With the success of CAR T-cell therapies for some blood cancers, Fred Hutch physician-scientists are taking a closer look to understand how patients respond to the therapy and what could be done to make the treatment work better.

Impact of Lisocabtagene Maraleucel (liso-cel) treatment on health-related quality of life and health utility in patients (pts) with relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (NHL): TRANSCEND NHL 001Physician-scientist Dr. David Maloney will present findings from the TRANSCEND trial for CD19 CAR T that show how patients had improved quality-of-life measures (reduced fatigue and pain symptoms) starting six months after receiving CAR T-cell therapy. As medical director of the Cellular Immunotherapy Integrated Research Center at Fred Hutch, Maloney is at the forefront of clinical trials to develop cell therapies for blood and other cancers, including understanding side effects of CAR Ts and how to deliver them in outpatient settings. He cares for patients at the Bezos Family Immunotherapy Clinic at Seattle Cancer Care Alliance, the Hutchs clinical-care partner.Abstract No. 66 (poster presentation)Saturday, Dec. 7, 8:45 a.m.W308, Level 3

Factors associated with response, CAR T cell in vivo expansion, and progression-free survival after repeat infusions of CD19 CAR T cellsDoes a second dose of CAR T cells help if the first doesnt lead to a lasting remission? A team of Fred Hutch physician-scientists led by Dr. Cameron Turtleexamined outcomes of 44 patients who received a second cycle of CD19 CAR T-cell immunotherapy for acute lymphoblastic leukemia, chronic lymphocytic leukemia or non-Hodgkin lymphoma. The type of chemotherapy given before the first infusion of CAR T cells and a higher dose of CAR T cells for the second infusion were associated with better outcomes.Abstract No. 201 (oral presentation)Saturday, Dec. 7, 12:30 p.m.Valencia A (W415A), Level 4

Severe cytokine release syndrome is associated with impaired hematopoietic recovery after CD19-targeted CART-cell therapyDr. Krishna Juluri, a hematology-oncology fellow at Fred Hutch, will discuss how blood cells recover following CAR T treatment. The researchers found patients who experienced more severe cytokine release syndrome had slower recovery of blood counts. Since CRS can be treated, the Fred Hutch team concludes preventing it might improve blood-cell recovery.Abstract No. 3229 (poster presentation)Sunday, Dec. 8, 68 p.m.Hall B, Level 2

Combination of NKTR-255, a polymer-conjugated human IL-15, with CD19 CAR T-cell immunotherapy in a preclinical lymphoma modelDr. Cassie Chou will present preclinical studies that show how a novel IL-15 receptor agonist activates the interleukin 15 immune system pathway to enhance growth and anti-tumor efficacy of human CD19 CAR T cells in immunodeficient mice bearing human lymphoma. Future clinical trials will explore whether the compound can improve responses to CAR T-cell therapy. Chou is a research fellow and clinician who works in the lab ofDr. Cameron Turtle. Abstract No. 2866 (poster presentation)Sunday, Dec. 8, 68 p.m.Hall B, Level 2

Relapsed or refractory CLL after CD19-specific CART therapy: Treatment patterns and clinical outcomesTreating high-risk chronic lymphocytic leukemia remains challenging with a 65% relapse rate following CAR T-cell therapy. Looking at outcomes of patients with progressive disease after CAR-T, Dr. Mazyar Shadman reports that CAR T-cell therapy did not work as well for patients who had already been treated with more than one other therapy for CLL. This study defines a benchmark for future trials that target relapsed CLL after CAR-T, and it also argues for referring patients to CAR T before they have exhausted other therapeutic options.Abstract No. 4294 (poster presentation)Monday, Dec. 9, 68 p.m.Hall B, Level 2

CD20 CAR T-CELL THERAPY

CD20 targeted chimeric antigen receptor T cells for treatment of high-risk B-cell non-Hodgkin lymphomasMost CAR T-cell therapies for blood cancers target a cancer-specific protein marker called CD19. But more targets are needed. Another CAR T-cell therapy that targets the CD20 protein on cancer cells is being developed by Fred Hutch scientists. Dr. Mazyar Shadman will give an overview of the trial, which is recruiting patients at the Hutchs clinical-care partner, Seattle Cancer Care Alliance. Results of the trial are not ready and will not be reported at ASH.Abstract No. 3235 (poster presentation)Sunday, Dec. 8, 68 p.m.Hall B, Level 2

_____________________________________________________________________________________________________________________

TRANSPLANTATION

Extending the benefit of transplantation to more patientsSirolimus combined with Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) As graft-vs-host disease (GVHD) prophylaxis after nonmyeloablative (NMA) hematopoietic cell transplantation (HCT) using HLA Class I or Class II antigen mismatched donors: Results from a Phase II multicenter trialStem cell transplants can save lives, but their success depends on the availability of compatible donors. Unfortunately, depending upon ethnicity, fully HLA-matched donors cannot be found for 25-84% of patients. Dr. Brenda Sandmaier is presenting results from a Phase 2 trial that shows how a triple-drug combination improves outcomes for patients treated with mismatched donors. Abstract No. 369 (oral presentation)Sunday, Dec. 8, 8 a.m.W230, Level 2

Cord blood transplantationTransplantation of blood stem cells from umbilical cord blood can treat blood disorders in patients who have been unable to find a suitable match among other donor sources. This is particularly true for patients of mixed ethnicities. Dr. Filippo Milano, associate director of Fred Hutchs Cord Blood Program, is involved in the following presentations.

_______________________________________________________________________________________________________________________

GENE THERAPY

Scientists in the lab of Dr. Hans-Peter Kiem, director of Fred Hutchs Stem Cell and Gene Therapy Program, are pioneering a variety of gene therapy approaches for HIV/AIDS, sickle cell anemia, blood cancers and other diseases. Below are their presentation abstracts.

Fully closed, large-scale, and clinical grade cell sorting of hematopoietic stem cell (HSC)-enriched CD90+ cells for transplantation and gene therapyDr. Stefan Radtke, a Fred Hutch staff scientist, will show for the first time in human blood samples how to isolate a rare stem cell subset that Fred Hutch researchers identified as capable of repopulating the entire blood and immune system. He used commercially available cell-sorting equipment to isolate the cells, an approach that has the potential to make gene therapy more efficient and affordable.Abstract No. 3246 (poster presentation)Sunday, Dec. 8, 68 p.m.Hall B, Level 2

CRISPR/Cas9-mediated protection of normal hematopoiesis combined with the CD33/CD3 bispecific T-cell engager (BiTE) antibody AMG330 for improved AML therapyCD33, a protein marker of cancerous cells in acute myeloid leukemia, is also found on healthy blood stem cells, which makes targeting CD33 toxic, as it kills both healthy cells and cancerous ones. Dr. Olivier Humbert, a staff scientist, used CRISPR to remove the CD33 target from healthy cells. Then, in a mouse model of acute myeloid leukemia, he found that T cells effectively use the CD33 bispecific T-cell engager (BiTE) antibody to attack cancer while sparing CRISPR-edited healthy cells.Abstract No. 4427 (poster presentation)Monday, Dec. 9, 68 p.m.Hall B, Level 2 _______________________________________________________________________________________________________________________

PRECISION MEDICINE / PEDIATRIC AML

Researchers from the lab of Dr. Soheil Meshinchi, a pediatric oncologist and acute myeloid leukemia specialist, will present oral presentations that map genetic mutations to patient outcomes. He says the ongoing genomic profiling work can help guide targeted treatments for patients with AML, the deadliest leukemia among children and young adults.

_______________________________________________________________________________________________________________________

ASH NOTABLES

ASH E. Donnall Thomas Lecture and PrizeThe long road to develop adoptive therapy for T cells that can effectively target acute myeloid leukemia and other malignanciesAt the annual E. Donnall Thomas Lecture, Dr. Philip Greenberg, head of the Program in Immunology at Fred Hutch, will talk about how T cells have been engineered to target acute myeloid leukemia and our latest understanding of why cell therapies like CAR T-cell therapy work for some patients and not others, but can potentially be engineered to overcome these obstacles. ASHs E. Donnall Thomas Lecture and Prize recognizes pioneering research achievements in hematology that have changed the field and is named for the Hutchs Dr. E. Donnall Thomas, who received a Nobel Prize for his pioneering efforts in bone marrow transplantation. Thomas was also a colleague and mentor to Greenberg. Learn more about the lecture in an ASH news release.Monday, Dec. 9, 910 a.m.Hall D, Level 2

Incoming ASH President Dr. Stephanie LeeASH will recognize Dr. Stephanie Lee, a hematologist and transplant physician-scientist at Fred Hutch, as its new president at the societys business meeting. Lee cares for stem cell transplant patients at the Hutchs clinical-care partner, Seattle Cancer Care Alliance, and at UW Medicine. Her research aims to improve the lives of transplant recipients. Lee directs the Hutchs Long-Term Follow-Up Research Program, which tracks the outcomes of more than 5,000 transplant survivors.Tuesday, Dec. 10, 11:1511:30 a.mHall D, Level 2

________________________________________________________________________________________________________________________

ON THE HORIZON / OTHER ABSTRACTS

Other notable experts and newsy topics at ASH:

Chronic myeloid leukemia: Meeting global need with better molecular testingDr. Jerald Radich is a medical oncologist who specializes in chronic myeloid leukemia, a relatively rare, slow-growing cancer that is fatal if left untreated. His Fred Hutch research lab examines the molecular genetics of leukemias in an effort to develop methods to improve the detection and treatment of the disease. At an ASH education session, Radich will talk about his award-winning collaboration with The Max Foundation, a Seattle-area nonprofit, which has led to more people in under-resourced areas being tested for CML. He will also give an oral presentation about a molecular test he developed that can predict which CML patients will have a sustained, deep molecular response to treatment.

Repairing immune function

Underappreciated by most, the thymus is a gland in the chest that acts like a boot camp for T cells, training them to identify and kill foreign invaders. The gland wears out with stress, infection and age, and finding ways to boost its productivity could help sustain human health. Researchers in the lab of Dr. Jarrod Dudakov, a Fred Hutch immunologist, will present the latest in understanding the signaling pathways of the thymus. Discovering master regulators could be targets for helping the thymus to repair itself. Below are their presentation abstracts.

_________________________________________________________________________________________________________________________

Note: Fred Hutch and its scientists who contributed to these discoveries may stand to benefit from their commercialization. See links above to ASH abstracts for more details on individual researchers disclosures.

The clinical trials referenced above involve investigational products and/or therapies that have not been approved for commercial marketing by the U.S. Food and Drug Administration or any other regulatory authority. Results may vary, and encouraging results from early-stage clinical trials may not be supported in later-stage clinical trials. No conclusions should be drawn from the information in this report about the safety, efficacy or likelihood of regulatory approval of these investigational products and/or therapies.

# # #

Media Contact:Molly McElroyO: 206.667.2210M: 206.941.8146mwmcelro@fredhutch.org

At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutchs pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nations first National Cancer Institute-funded cancer prevention research program, as well as the clinical coordinating center of the Womens Health Initiative and the international headquarters of the HIV Vaccine Trials Network.

See the article here:
Fred Hutch at ASH: Latest CAR T data BCMA, CD19, CD20 plus new insights on transplantation, gene therapy and more - Newswise

Stem Cell Alopecia Treatment Market: moving from experimentation to transformation in 2024 – WindStreetz

Stem Cell Alopecia Treatment Market Forecast (2019-2024):The latest Stem Cell Alopecia Treatment Market reviews most recent patterns saw in the worldwide market. This insight study centers around the most recent occasions, for example, the mechanical improvements, item dispatches and their outcomes on the worldwide market. The market comprises of information amassed from various essential and auxiliary sources. This information has been substantiated and approved by the business experts and specialists, subsequently giving huge bits of knowledge to the scientists, examiners, supervisors, and other industry leaders.

Avail a Sample copy of This Report @ https://www.alexareports.com/report-sample/42629

The research also includes an in-depth analysis of the quantitative and qualitative aspects by numerous industry professionals and key opinion leaders, in order to gain a detailed insight into the market and industry performance. The report provides a comprehensive insight of the present market landscape, including the historical and future market size with regards to the technical advancements, value, volume, micro- and macro-economical factors, governing factors, and development patterns in the market. The report also sheds light on the key strategies undertaken by the leading competitors operating in the market.

The report also provides a detailed comprehension of the major geographies included in the market, along with the key segments and sub-segments. The report provides a regional development status, which includes the market size and share, value and volume, as well as price data. Additionally, this report covers the manufacturers data, including business distribution, shipment, gross profit, cost, price, revenue, interview record etc.,

which allows the consumers in better understanding about the leading competitors operating in the market. Key players in the market include Riken Research Institute, Belgravia Center, APEX Biologix, RepliCel, Kerastem, Sanford Burnham Prebys Medical Discovery Institute,

By Types: Alopecia Areata, Alopecia Totalis, Alopecia Universalis

By Applications: Hospitals, Clinic, Others

Avail Discount on This Report @ https://www.alexareports.com/check-discount/42629

Key Target Audience:

Additional Information:

This report provides:

Key Questions Answered in the Report are:

Do Enquiry Before Buying @ https://www.alexareports.com/send-an-enquiry/42629

See original here:
Stem Cell Alopecia Treatment Market: moving from experimentation to transformation in 2024 - WindStreetz

Koepka withdraws from Presidents Cup, replaced by Fowler – Newscenter1.tv

ERROR: The request could not be satisfiedRequest blocked.We can't connect to the server for this app or website at this time. There might be too much traffic or a configuration error. Try again later, or contact the app or website owner.If you provide content to customers through CloudFront, you can find steps to troubleshoot and help prevent this error by reviewing the CloudFront documentation.Generated by cloudfront (CloudFront)Request ID: Tyz0sF96ZX1IiZHZjn4Xfv4ztagQIGiYWvshVlVTfhhfIN0iCDg7Dw==

View original post here:
Koepka withdraws from Presidents Cup, replaced by Fowler - Newscenter1.tv

Vor Biopharma and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Hematopoietic Stem Cells (eHSCs) to Treat Cancer -…

CAMBRIDGE, Mass. & GAITHERSBURG, Md.--(BUSINESS WIRE)--Vor Biopharma, an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, and MaxCyte, Inc., a global cell-based therapies and life sciences company, today announced a clinical and commercial license agreement under which Vor will use MaxCytes Flow Electroporation technology to produce eHSCs and initiate Investigational New Drug (IND)-enabling studies to accelerate its progress towards the clinic.

Under the terms of the agreement, Vor obtains non-exclusive clinical and commercial use rights to MaxCytes Flow Electroporation technology and ExPERT platform to develop up to five engineered cell therapies, including VOR33, Vors lead eHSC candidate, which is in development for acute myeloid leukemia (AML). In return, MaxCyte will receive undisclosed development and approval milestones and sales-based payments in addition to other licensing fees.

Vor will use MaxCytes cell engineering platform to deliver its gene editing machinery into hematopoietic stem cells to remove biologically redundant cell surface proteins that are also expressed on blood cancer cells. Once the eHSCs are transplanted into a cancer patient, these cells are effectively hidden from complementary targeted therapies that target the relevant protein, while diseased cells are left vulnerable to attack. Vors approach thereby could unleash the potential of targeted therapies by broadening the therapeutic window and improving the utility of complementary targeted therapies.

MaxCyte is a leader in GMP electroporation technology, and we are thrilled that this agreement provides us with long-term access to a platform technology applicable to a pipeline of eHSC programs used to treat AML and other blood cancers, said Sadik Kassim, Ph.D., Chief Technology Officer of Vor. As we build on promising in vivo data from our lead candidate VOR33, we can now expand our manufacturing capabilities to support later-stage studies, regulatory filings and commercialization of VOR33.

MaxCytes ExPERT instrument family represents the next generation of leading, clinically validated, electroporation technology for complex and scalable cellular engineering. By delivering high transfection efficiency with enhanced functionality, the ExPERT platform delivers the high-end performance essential to enable the next wave of biological and cellular therapeutics.

We look forward to expanding our relationship with Vor Biopharma as the company pioneers a potential future standard of care in hematopoietic stem cell transplants for cancer patients in need, said Doug Doerfler, President & CEO of MaxCyte. This agreement represents another key business milestone for MaxCyte, emphasizing the value of our technology platform applied to next-generation engineered cell therapies that may make a true difference in patient outcomes.

About VOR33Vors lead product candidate, VOR33, consists of engineered hematopoietic stem cells (eHSCs) that lack the protein CD33. Once these cells are transplanted into a cancer patient, CD33 becomes a far more cancer-specific target, potentially avoiding toxicity to the normal blood and bone marrow associated with CD33-targeted therapies. In so doing, Vor aims to improve the therapeutic window and effectiveness of CD33-targeted therapies, thereby potentially broadening the clinical benefit to patients suffering from AML.

About Vor BiopharmaVor Biopharma aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell (eHSC) therapies. By removing biologically redundant proteins from eHSCs, these cells become inherently invulnerable to complementary targeted therapies while tumor cells are left susceptible, thereby unleashing the potential of targeted therapies to benefit cancer patients in need.

Vors platform could be used to potentially change the treatment paradigm of both hematopoietic stem cell transplants and targeted therapies, such as antibody drug conjugates, bispecific antibodies and CAR-T cell treatments. A proof-of-concept study for Vors lead program has been published in Proceedings of the National Academy of Sciences.

Vor is based in Cambridge, Mass. and has a broad intellectual property base, including in-licenses from Columbia University, where foundational work was conducted by inventor and Vor Scientific Board Chair Siddhartha Mukherjee, MD, DPhil. Vor was founded by Dr. Mukherjee and PureTech Health and is supported by leading investors including 5AM Ventures and RA Capital Management, Johnson & Johnson Innovation JJDC, Inc. (JJDC), Novartis Institutes for BioMedical Research and Osage University Partners.

About MaxCyteMaxCyte is a clinical-stage global cell-based therapies and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet medical needs. MaxCyte is developing novel CARMA therapies for its own pipeline, with its first drug candidate in a Phase I clinical trial. CARMA is MaxCytes mRNA-based proprietary therapeutic platform for autologous cell therapy for the treatment of solid cancers. In addition, through its life sciences business, MaxCyte leverages its Flow Electroporation Technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. MaxCyte has placed its flow electroporation instruments worldwide, including with all of the top ten global biopharmaceutical companies. The Company now has more than 80 partnered programme licenses in cell therapy with more than 45 licensed for clinical use. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit http://www.maxcyte.com.

See original here:
Vor Biopharma and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Hematopoietic Stem Cells (eHSCs) to Treat Cancer -...

CALQUENCE Approved in the US for Adult Patients With Chronic Lymphocytic Leukemia – Business Wire

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved CALQUENCE (acalabrutinib) for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The US approval was granted under the FDAs Real-Time Oncology Review and newly established Project Orbis programs.

The approval is based on positive results from the interim analyses of two Phase III clinical trials, ELEVATE-TN in patients with previously untreated CLL and ASCEND in patients with relapsed or refractory CLL. Together, the trials showed that CALQUENCE in combination with obinutuzumab or as a monotherapy significantly reduced the relative risk of disease progression or death versus the comparator arms in both 1st-line and relapsed or refractory CLL. Across both trials, the safety and tolerability of CALQUENCE were consistent with its established profile.

Dave Fredrickson, Executive Vice President, Oncology Business Unit said: With over 20,000 new cases anticipated this year in the US alone, todays approval of CALQUENCE provides new hope for patients with one of the most common types of adult leukemia, offering outstanding efficacy and a favorable tolerability profile. The chronic lymphocytic leukemia patient population is known to face multiple comorbidities, and tolerability is a critical factor in their treatment.

Dr. Jeff Sharman, Director of Research at Willamette Valley Cancer Institute, Medical Director of Hematology Research for The US Oncology Network, and a lead author of the ELEVATE-TN trial, said: Tolerability remains an issue in the current treatment landscape of chronic lymphocytic leukemia, which may require ongoing therapy for many years. In the ELEVATE-TN and ASCEND trials comparing CALQUENCE to commonly used treatment regimens, CALQUENCE demonstrated a clinically meaningful improvement in progression-free survival in patients across multiple settings, while maintaining its favorable tolerability and safety profile.

The results of the interim analysis of the ELEVATE-TN trial will be presented at the upcoming American Society of Hematology congress.

The trial showed a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for patients treated with either CALQUENCE in combination with obinutuzumab or CALQUENCE monotherapy versus chlorambucil chemotherapy plus obinutuzumab, a current standard-of-care combination used in the control arm.

In the CALQUENCE combination arm, risk of disease progression or death was reduced by 90% (HR 0.10; 95% CI, 0.06-0.17, p<0.0001) and in the monotherapy arm it was reduced by 80% (HR 0.20; 95% CI, 0.13-0.30, p<0.0001).

The median time to disease progression for patients treated with CALQUENCE in combination with obinutuzumab or as a monotherapy has not yet been reached vs. 22.6 months (95% CI, 20-28) for chlorambucil plus obinutuzumab.

ELEVATE-TN safety overview (most common ARs*, 15%):

Adverse reaction

CALQUENCE plus obinutuzumab(n=178)

CALQUENCE monotherapy(n=179)

Chlorambucil plus obinutuzumab(n=169)

Any

Grade 3

Any

Grade 3

Any

Grade 3

Infection

69%

22%

65%

14%

46%

13%

Neutropenia

53%

37%

23%

13%

78%

50%

Anemia

52%

12%

53%

10%

54%

14%

Thrombocytopenia

51%

12%

32%

3.4%

61%

16%

Headache

40%

1.1%

39%

1.1%

12%

0

Diarrhea

39%

4.5%

35%

0.6%

21%

1.8%

Musculoskeletal pain

37%

2.2%

32%

1.1%

16%

2.4%

Fatigue

34%

2.2%

23%

1.1%

24%

1.2%

Bruising

31%

0

21%

0

5%

0

Rash

26%

2.2%

25%

0.6%

9%

0.6%

Arthralgia

22%

1.1%

16%

0.6%

4.7%

1.2%

Dizziness

20%

0

12%

See more here:
CALQUENCE Approved in the US for Adult Patients With Chronic Lymphocytic Leukemia - Business Wire

Full Alliance Group Announces New EBO2 Sites in Florida and the Caribbean – P&T Community

BEVERLY HILLS, California, Nov. 21, 2019 /PRNewswire/ -- Full Alliance Group, Inc. (OTCPK: FAGI) is pleased to announce the opening of two new EBO2 treatment offices.

Dr. Yu and his staff arrived in Boca Raton, Florida, and then the Cayman Islands earlier this week with two brand-new portable EBO2 units and are currently training Dr. Joseph Purita and his staff. Dr. Purita is well-known in the stem cell and regenerative medicine sector and is eager to implement our ozone technology within his thriving practice.He has offices in Boca Raton as well as in the Cayman Islands.

Dr. Purita's Pensum Regenerative Clinic in Grand Cayman already specializes in stem cell treatment and anti-aging.The addition of EBO2 technology is expected to work synergistically with the well-established stem cell protocols already in place at the clinic.

"Expanding our footprint to the East and South, as well as the Caribbean, has been a critical part of our strategic plan," said Dr. Brian Volpp, MD, CEO and President of Full Alliance Group, Inc. "We are grateful that Dr. Purita has committed to the Yu Method and that he has made the financial commitment for two of our new units.His reputation within the stem cell community should allow ozone therapy to become more mainstream as he gains more experience with integrating EBO2 into his existing protocols."

Also, we have been advised by our legal team that the third quarter financial filing must be made publicly available to all shareholders. Consequently, the filing has been posted on our website:https://FullAlliance.com

About Full Alliance Group Inc.

Full Alliance Group Inc. (OTCPK: FAGI) is a multi-faceted holding company with various interests in technology, healthcare, and nutraceuticals. Nutra Yu, Inc., a wholly owned subsidiary of Full Alliance Group, develops, markets, and distributes a proprietary line of nutraceutical products. EBO2, Inc., a wholly owned subsidiary of Full Alliance Group, is the provider of ''EBO2'', a modern high volume blood gas exchange unit for the treatment of 5-7 liters of blood with medical ozone. The unit allows extracorporeal blood and oxygenation, ozone exposure and blood filtration.The process filters blood in a unique way by using the integrated diffusing membranes within the filter fibers to trap lipids and proteins which are in excess in the venous blood supply. The EBO2 unit is considered the world's most advanced medical ozone therapy.

For additional information regarding Full Alliance Group, visit, http://www.fullalliance.com.

Paul Brian Volpp, MD, MPH, President / CEO The Full Alliance Group

Forward-Looking StatementsThis shareholder update may contain a number of forward-looking statements. Words and variations of words such as: "expect", "goals", "could", "plans", "believe", "continue", "may", "will", and similar expressions are intended to identify our forward-looking statements, including but not limited to: our expectation for growth, benefits from brand-building, cost savings and margins. These forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond our control, which could cause our actual results to differ materially from those indicated in our forward-looking statements. Such factors include, but are not limited to: continued volatility of, and sharp increase in: costs/pricing actions, increased competition, ability to raise sufficient operating capital, risks from operating internationally, consumer weakness, weakness in economic conditions and tax law changes.

Full Alliance Group Inc. Investor RelationsDave DonlinEmail: Info@TheCervelleGroup.comPhone: (407) 490-6635Web: http://www.StockInvestorDaily.comVisit: http://www.fullalliance.comContact: ir@fullalliance.com

View original content:http://www.prnewswire.com/news-releases/full-alliance-group-announces-new-ebo2-sites-in-florida-and-the-caribbean-300963216.html

SOURCE Full Alliance Group, Inc.

See more here:
Full Alliance Group Announces New EBO2 Sites in Florida and the Caribbean - P&T Community

Multiple Doses of Stem Cells Show Potential in Treating Severe Asthma – PR Web

Inflammatory and remodeling processes and immunosuppressive effects in house dust mite (HDM)-induced allergic asthma.

DURHAM, N.C. (PRWEB) November 20, 2019

A study released today in STEM CELLS Translational Medicine (SCTM) describes how multiple doses of a type of stem cell called mesenchymal stromal cells (MSCs) might offer a new way to treat people suffering from severe asthma.

An asthma attack is triggered by allergens entering the lungs and causing swelling of the airways. This sets off a domino effect that results in narrowing of the airways from the nose and mouth to the lungs. The most severe cases can lead to death. According to the Centers for Disease Control and Prevention, one in 13 people have asthma. There is no cure, but it can be managed in most cases with proper prevention and treatment.

The study in SCTM, conducted by researchers at the Federal University of Rio de Janeiro and the National Institute of Science and Technology for Regenerative Medicine, focused on a new treatment for asthma brought on by house dust mites (HDMs). Some estimate that these common microscopic creatures are the culprit behind nearly 85 percent of all asthma attacks.

Patricia Rieken Macedo Rocco, M.D., Ph.D., was lead investigator on the study. Previous experiments tell us that a single dose of adipose tissue-derived MSCs reduced lung inflammation in asthma brought on by HDMs, but it was unable to reverse lung remodeling, she said. We wanted to see how multiple doses of MSCs might perform.

Earlier studies using bone marrow-derived MSCs also demonstrated therapeutic effects in HDM-induced allergic asthma, but the availability of these cells is limited due to the invasive procedure needed to harvest the cells. We opted for MSCs collected from human adipose tissue instead, as they can be easily obtained by liposuction, Dr. Rocco explained. Furthermore, adipose tissue is estimated to contain a greater number of MSCs compared to bone marrow, and these cells appear to be expandable to a higher number of passages, thus providing attractive advantages for use in a multiple-dose regimen.

For their study, the team used a mouse model that had been developed to be sensitive to HDMs. One group of animals received two intravenous doses of MSCs (105 cells/day) beginning 24 hours after being exposed to the mites; a second group received three doses; and a third group was administered dexamethasone, a steroid often used to treat experimental asthma. A control group was given saline only.

After seven days, the animals treated with the two and three doses of MSCs showed reduced lung inflammation and remodeling, improved lung function and T-cell immunosuppression, with the three-dose regimen proving the most effective.

MSC-induced immunosuppression has been reported in models of autoimmune disorders and in early-stage clinical trials, with some promising results for the treatment of graft versus host disease, multiple sclerosis, systemic lupus erythematosus and other conditions. But this is the first study demonstrating that multiple doses of MSCs may induce immunosuppressive effects in experimental allergic asthma, Dr. Rocco said.

These findings should be borne in mind for future clinical trials in patients with severe asthma.

Outcomes from this study highlight the potential of mesenchymal stromal cells to reduce lung inflammation caused by asthma, which affects more than 25 million people in America alone, said Anthony Atala, M.D., Editor-in-Chief of SCTM and director of the Wake Forest Institute for Regenerative Medicine. Larger clinical studies will be welcomed to further verify the safety and efficacy of this treatment.

The full article, Multiple Doses of Adipose Tissue-Derived Mesenchymal Stromal Cells Induce Immunosuppression in Experimental Asthma, can be accessed at https://stemcellsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/sctm.19-0120.

About STEM CELLS Translational Medicine: STEM CELLS Translational Medicine (SCTM), co-published by AlphaMed Press and Wiley, is a monthly peer-reviewed publication dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices. SCTM is the official journal partner of Regenerative Medicine Foundation.

About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes two other internationally renowned peer-reviewed journals: STEM CELLS, is the world's first journal devoted to this fast paced field of research. The Oncologist (http://www.TheOncologist.com), also a monthly peer-reviewed publication, is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. All three journals are premier periodicals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines.

About Wiley: Wiley, a global company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical and scholarly journals, combined with our digital learning, assessment and certification solutions, help universities, learned societies, businesses, governments and individuals increase the academic and professional impact of their work. For more than 200 years, we have delivered consistent performance to our stakeholders. The company's website can be accessed at http://www.wiley.com.

About Regenerative Medicine Foundation (RMF): The non-profit Regenerative Medicine Foundation fosters strategic collaborations to accelerate the development of regenerative medicine to improve health and deliver cures. RMF pursues its mission by producing its flagship World Stem Cell Summit, honouring leaders through the Stem Cell and Regenerative Medicine Action Awards, and promoting educational initiatives.

Share article on social media or email:

Read more here:
Multiple Doses of Stem Cells Show Potential in Treating Severe Asthma - PR Web